Genetic Variants of the NKG2C/HLA-E Receptor-Ligand Axis Are Determinants of Progression-Free Survival and Therapy Outcome in Aggressive B-Cell Lymphoma.
HLA-E
NHL
NKG2C
aggressive lymphoma
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
18 Nov 2020
18 Nov 2020
Historique:
received:
13
10
2020
revised:
14
11
2020
accepted:
15
11
2020
entrez:
21
11
2020
pubmed:
22
11
2020
medline:
22
11
2020
Statut:
epublish
Résumé
Aggressive B-cell lymphomas account for the majority of non-Hodgkin lymphomas (B-NHL). NK cells govern the responses to anti-CD20 monoclonal antibodies and have emerged as attractive targets for immunotherapy in subtypes of B-NHL. NKG2C and its cognate ligand HLA-E represent key molecules for fine-tuning of NK cell-mediated immune responses. Here, we investigated the impact of genetic variants of
Identifiants
pubmed: 33218185
pii: cancers12113429
doi: 10.3390/cancers12113429
pmc: PMC7699209
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Deutsche Krebshilfe
ID : 107592
Organisme : Deutsche Krebshilfe
ID : 109816
Organisme : Deutsche Krebshilfe
ID : 110515
Références
Immunogenetics. 2003 Feb;54(11):767-75
pubmed: 12618909
J Immunol. 2012 May 1;188(9):4412-20
pubmed: 22490439
Eur J Immunol. 1999 Feb;29(2):537-47
pubmed: 10064069
Front Immunol. 2019 Sep 12;10:2085
pubmed: 31572357
Haematologica. 2003 Sep;88(9):1002-12
pubmed: 12969808
Tissue Antigens. 2014 Feb;83(2):82-93
pubmed: 24400773
Curr Top Microbiol Immunol. 2016;395:115-45
pubmed: 26025472
J Biol Chem. 2003 Feb 14;278(7):5082-90
pubmed: 12411439
Tissue Antigens. 2002 Sep;60(3):206-12
pubmed: 12445303
J Immunol Res. 2016;2016:2695396
pubmed: 27699181
Tissue Antigens. 2004 Nov;64(5):588-92
pubmed: 15496202
Nat Med. 2018 May;24(5):679-690
pubmed: 29713087
Tissue Antigens. 2015 Aug;86(2):98-113
pubmed: 26189878
J Biomed Sci. 1998 Sep-Oct;5(5):321-31
pubmed: 9758906
Eur J Immunol. 2016 Apr;46(4):929-40
pubmed: 26711740
Eur J Immunol. 2013 Dec;43(12):3268-78
pubmed: 24030638
PLoS One. 2015 Aug 11;10(8):e0135512
pubmed: 26261988
Blood. 2014 Feb 6;123(6):837-42
pubmed: 24264230
J Clin Oncol. 2005 Aug 1;23(22):5027-33
pubmed: 15955905
Cell. 2018 Dec 13;175(7):1731-1743.e13
pubmed: 30503213
Nature. 1998 Feb 19;391(6669):795-9
pubmed: 9486650
Blood. 2007 Apr 1;109(7):2806-14
pubmed: 17179229
Int Immunol. 2004 Jan;16(1):163-8
pubmed: 14688071
J Clin Oncol. 2018 Jul 10;36(20):2024-2034
pubmed: 29750632
J Nucl Med. 2007 Oct;48(10):1626-32
pubmed: 17873129
Int J Immunogenet. 2014 Apr;41(2):126-30
pubmed: 24305414
Blood. 2004 Dec 1;104(12):3664-71
pubmed: 15304389
Cancer. 2017 Mar 1;123(5):814-823
pubmed: 27859015
Br J Haematol. 2019 Jun;185(6):1055-1070
pubmed: 30613939
Cancer Sci. 2015 May;106(5):522-8
pubmed: 25711417
Tissue Antigens. 2012 Aug;80(2):184-7
pubmed: 22708664
Blood. 2014 Dec 18;124(26):3870-9
pubmed: 25359988
Hum Immunol. 1990 Oct;29(2):131-42
pubmed: 2249951
Genes Immun. 2003 Mar;4(2):160-7
pubmed: 12618865
J Infect Dis. 2018 Feb 14;217(5):802-806
pubmed: 29220498
J Immunol. 2005 Mar 1;174(5):2878-84
pubmed: 15728498
AIDS Res Hum Retroviruses. 2012 Aug;28(8):844-51
pubmed: 22074011
Blood. 2013 Jan 3;121(1):156-8
pubmed: 23160463
J Infect Dis. 2018 May 25;217(12):1918-1922
pubmed: 29228302
Exp Dermatol. 2013 Oct;22(10):679-81
pubmed: 24079744
Semin Immunol. 2014 Apr;26(2):145-51
pubmed: 24666761
N Engl J Med. 1993 Sep 30;329(14):987-94
pubmed: 8141877
J Clin Oncol. 2010 May 10;28(14):2373-80
pubmed: 20385988
Eur J Immunol. 2005 Jul;35(7):2071-80
pubmed: 15940674
Leuk Lymphoma. 2019 Jan;60(1):208-215
pubmed: 29969046